The SWOG S1512 trial highlights the potential of immunotherapy in treating desmoplastic melanoma, emphasizing the need for innovative approaches in rare cancer trials. Experts suggest that leveraging electronic health records and AI can enhance patient recruitment and trial design in these challenging areas.
Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states. Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states. ... Immunotherapy has dramatically changed the prognosis of many cancers, and now attention is turning to rare disease states where clinical trials are more challenging to run. Electronic health records have made it more efficient to identify potential patients for clinical trials, including those for rare diseases and molecular targets across all cancers. Knudsen feels that artificial intelligence (AI) can go beyond this and guide decisions on how a particular cancer center or group can successfully build a trial in an area of great need. Patients in remission are also increasingly seeking solutions to prevent disease recurrence, illustrating the need for powerful targeted therapies that don’t compromise quality of life. Knudsen sees immunotherapy and vaccines as filling this role as well. Although ICIs are widely accessible to patients, other immune-based treatments, such as chimeric antigen receptor (CAR) T-cell therapies, can be administered only under strict monitoring at designated academic centers. AI can also aid in synchronizing data collection between hospital records and clinical trial investigators. This can address bottlenecks that form and allow more trials to open. Initially, the decline in cancer mortality that has been observed in the United States since 1991 was largely attributed to cancer prevention strategies. Now, Knudsen said, declines in mortality from lung cancer, liver cancer, multiple myeloma, and melanoma are instead reflections of the role of therapy in prolonging survival.6 “What’s the common denominator in all of those?
Original title: “Rare Melanoma Trial Serves as Model for Advancing Cancer Immunotherapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways”